Abbott Laboratories Company Profile (NYSE:ABT)

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry, Sector and Symbol:

Sector: Medical
Industry: Pharmaceuticals
Sub-Industry: Health Care Equipment
Symbol: NYSE:ABT
CUSIP: 00282410
Web: www.abbott.com

Capitalization:

Market Cap: $97.3 billion
Outstanding Shares: 1,737,443,000

Average Prices:

50 Day Moving Avg: $52.94
200 Day Moving Avg: $48.37
52 Week Range: $37.38 - $56.60

P/E:

Trailing P/E Ratio: 78.43
Foreward P/E Ratio: 19.86
P/E Growth: 2.16

Sales & Book Value:

Annual Revenue: $23.61 billion
Price / Sales: 4.12
Book Value: $18.19 per share
Price / Book: 3.08

Dividend:

Annual Dividend: $1.06
Dividend Yield: 1.9%

Profitability:

EBITDA: $5.14 billion
Net Margins: 4.96%
Return on Equity: 14.43%
Return on Assets: 6.47%

Debt:

Debt-to-Equity Ratio: 0.75%
Current Ratio: 2.94%
Quick Ratio: 2.41%

Misc:

Average Volume: 5.61 million shs.
Beta: 1.06
Short Ratio: 2.35

Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Friday, September 15th. Shareholders of record on Friday, October 13th will be paid a dividend of $0.265 per share on Wednesday, November 15th. This represents a $1.06 annualized dividend and a yield of 1.89%. The ex-dividend date is Thursday, October 12th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) posted its quarterly earnings data on Wednesday, October, 18th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.65 by $0.01. The business had revenue of $6.83 billion for the quarter, compared to analysts' expectations of $6.72 billion. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. Abbott Laboratories's quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.59 earnings per share. View Abbott Laboratories' Earnings History.

When will Abbott Laboratories make its next earnings announcement?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January, 24th 2018. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories issued an update on its fourth quarter earnings guidance on Wednesday, October, 18th. The company provided earnings per share guidance of $0.72-0.74 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.73.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

14 brokers have issued twelve-month price objectives for Abbott Laboratories' shares. Their forecasts range from $42.00 to $68.00. On average, they anticipate Abbott Laboratories' share price to reach $57.64 in the next year. View Analyst Ratings for Abbott Laboratories.

What are analysts saying about Abbott Laboratories stock?

Here are some recent quotes from research analysts about Abbott Laboratories stock:

1. According to Zacks Investment Research, "Over the past three months, Abbott has been trading above the broader industry. While we await Abbott's third-quarter 2017 earnings result, the promising full year guidance is indicative of brighter prospects ahead. In fact, the strong guidance is backed by the company’s expectations to gain more synergies from the St. Jude merger. Overall, we look forward to Abbott’s plans to expand in core therapeutic areas. Recently, the company's FreeStyle Libre Flash received the FDA approval. Also, the company has received FDA approval for magnetic resonance-conditional labeling for its Ellipse implantable cardioverter defibrillator recently. On the flip side, Abbott’s sluggish pediatric business in China continues to dent growth. Management is also concerned about the economic problems in Venezuela that are expected to remain unresolved for some time. Meanwhile, we still wait for the Alere integration details." (10/16/2017)
2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)

Who are some of Abbott Laboratories' key competitors?

Some companies that are related to Abbott Laboratories include Merck & Company (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Celgene Corporation (CELG), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Patheon NV (PTHN) and Taro Pharmaceutical Industries (TARO).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:

Miles D. White, Chairman of the Board, Chief Executive Officer
Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
Michael T. Rousseau, President - Cardiovascular and Neuromodulation
Hubert L. Allen, Executive Vice President, General Counsel, Secretary
Stephen R. Fussell, Executive Vice President - Human Resources
Brian J. Blaser, Executive Vice President - Diagnostics Products
John M. Capek Ph.D., Executive Vice President - Ventures
Robert B. Ford, Executive Vice President - Medical Devices
Heather L. Mason, Executive Vice President - Nutritional Products
Roger Bird, Senior Vice President - U.S. Nutrition

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Park National Corp OH (0.03%), Tandem Investment Advisors Inc. (0.01%), Osborn Williams & Donohoe LLC (0.01%), Bath Savings Trust Co (0.00%), McQueen Ball & Associates Inc. (0.00%) and Curbstone Financial Management Corp (0.00%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Bridges Investment Counsel Inc., Private Asset Management Inc., Osborn Williams & Donohoe LLC, Tandem Investment Advisors Inc., Eqis Capital Management Inc. and Bath Savings Trust Co. Company insiders that have sold Abbott Laboratories stock in the last year include Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp, Park National Corp OH and McQueen Ball & Associates Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of Abbott Laboratories stock can currently be purchased for approximately $56.00.

MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		585 (Vote Outperform)
Underperform Votes:		433 (Vote Underperform)
Total Votes:		1,018

MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Abbott Laboratories (NYSE:ABT) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	5 Hold Ratings, 9 Buy Ratings
Consensus Rating:	Buy (Score: 2.64)
Consensus Price Target:	$57.64 (2.93% upside)

Consensus Price Target History for Abbott Laboratories (NYSE:ABT)

Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
10/19/2017	Barclays PLC	Reiterated Rating	Overweight		N/A
10/19/2017	Citigroup Inc.	Reiterated Rating	Neutral		N/A
10/19/2017	BMO Capital Markets	Reiterated Rating	Market Perform		N/A
10/19/2017	Cowen and Company	Set Price Target	Buy	$55.00 -> $68.00	N/A
10/19/2017	Stifel Nicolaus	Boost Price Target	Buy -> Buy	$58.00 -> $63.00	N/A
10/19/2017	Royal Bank Of Canada	Boost Price Target	Outperform -> Outperform	$55.00 -> $60.00	N/A
10/19/2017	Jefferies Group LLC	Reiterated Rating	Buy	$65.00	N/A
10/6/2017	J P Morgan Chase & Co	Initiated Coverage	Neutral -> Neutral	$60.00	N/A
10/4/2017	Bank of America Corporation	Reiterated Rating	Buy	$56.00 -> $60.00	N/A
9/28/2017	Wells Fargo & Company	Boost Price Target	Outperform	$57.00 -> $64.00	Low
7/10/2017	Morgan Stanley	Reiterated Rating	Equal Weight		Low
6/29/2017	Guggenheim	Initiated Coverage	Buy	$58.00	Low
6/21/2017	BTIG Research	Initiated Coverage	Buy	$56.00	Low
5/16/2017	Goldman Sachs Group, Inc. (The)	Initiated Coverage	Neutral -> Neutral	$45.00	Low
8/9/2016	Deutsche Bank AG	Reiterated Rating	Buy		N/A
7/28/2016	Argus	Reiterated Rating	Buy	$55.00	N/A
6/21/2016	Edward Jones	Upgrade	Hold -> Buy		N/A
6/8/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A
4/30/2016	S&P Equity Research	Reiterated Rating	Hold		N/A
4/30/2016	Gabelli	Reiterated Rating	Buy		N/A
4/28/2016	Piper Jaffray Companies	Downgrade	Overweight -> Neutral		N/A
4/14/2016	First Global	Downgrade	Outperform -> Marketperform		N/A
3/28/2016	Leerink Swann	Boost Price Target	Market Perform	$37.00 -> $40.00	N/A
1/29/2016	Raymond James Financial, Inc.	Lower Price Target	Outperform	$46.00 -> $42.00	N/A
1/29/2016	William Blair	Downgrade	Outperform -> Market Perform		N/A

(Data available from 10/19/2015 forward)

Earnings History for Abbott Laboratories (NYSE:ABT)

Earnings by Quarter for Abbott Laboratories (NYSE:ABT)

Earnings History by Quarter for Abbott Laboratories (NYSE ABT)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
1/24/2018
10/18/2017	9/30/2017	$0.65	$0.66	$6.72 billion	$6.83 billion	View	N/A
7/20/2017	Q2 2017	$0.60	$0.62	$6.63 billion	$6.64 billion	View	N/A
4/19/2017	3/31/2017	$0.43	$0.48	$6.16 billion	$6.34 billion	View	N/A
1/25/2017	Q416	$0.64	$0.65	$5.41 billion	$5.33 billion	View	Listen
10/19/2016	Q316	$0.58	$0.59	$5.29 billion	$5.30 billion	View	Listen
7/20/2016	Q216	$0.53	$0.55	$5.24 billion	$5.30 billion	View	Listen
4/20/2016	Q116	$0.39	$0.41	$4.77 billion	$4.90 billion	View	Listen
1/28/2016	Q415	$0.61	$0.62	$5.31 billion	$5.20 billion	View	Listen
10/21/2015	Q315	$0.53	$0.54	$5.16 billion	$5.15 billion	View	Listen
7/22/2015	Q215	$0.50	$0.52	$5.15 billion	$5.20 billion	View	Listen
4/22/2015	Q115	$0.42	$0.47	$4.85 billion	$4.90 billion	View	Listen
1/29/2015	Q414	$0.68	$0.71	$5.48 billion	$5.36 billion	View	Listen
10/22/2014	Q314	$0.60	$0.62	$5.62 billion	$5.10 billion	View	Listen
7/16/2014	Q214	$0.51	$0.54	$5.53 billion	$5.55 billion	View	Listen
4/16/2014	Q114	$0.36	$0.41	$5.29 billion	$5.24 billion	View	Listen
1/22/2014	Q413	$0.58	$0.58	$5.72 billion	$5.66 billion	View	Listen
10/16/2013	Q313	$0.52	$0.55	$5.46 billion	$5.37 billion	View	Listen
7/17/2013	Q2 2013	$0.44	$0.46	$5.53 billion	$5.45 billion	View	Listen
4/17/2013	Q1 2013	$0.41	$0.42	$5.42 billion	$5.38 billion	View	Listen
1/23/2013	Q4 2012	$1.50	$1.51	$10.58 billion	$10.80 billion	View	Listen
10/17/2012		$1.28	$1.30			View	N/A
7/18/2012		$1.22	$1.23			View	N/A
4/18/2012		$1.00	$1.03			View	N/A
1/25/2012		$1.44	$1.45			View	N/A
10/19/2011		$1.17	$1.18			View	N/A
7/20/2011		$1.12	$1.12			View	N/A
4/20/2011		$0.90	$0.91			View	N/A
1/26/2011		$1.29	$1.30			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Abbott Laboratories (NYSE:ABT)

2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.83

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	3	$0.43	$0.50	$0.45
Q2 2017	3	$0.59	$0.61	$0.60
Q3 2017	3	$0.64	$0.68	$0.66
Q4 2017	3	$0.72	$0.73	$0.73
Q1 2018	2	$0.55	$0.56	$0.56
Q2 2018	2	$0.69	$0.71	$0.70
Q3 2018	2	$0.74	$0.76	$0.75
Q4 2018	2	$0.80	$0.84	$0.82

(Data provided by Zacks Investment Research)

Current Dividend Information for Abbott Laboratories (NYSE:ABT)

Next Dividend:	11/15/2017
Annual Dividend:	$1.06
Dividend Yield:	1.89%
Dividend Growth:	22.90% (3 Year Average)
Payout Ratio:	149.30% (Trailing 12 Months of Earnings) 42.40% (Based on This Year's Estimates) 37.59% (Based on Next Year's Estimates)
Track Record:	44 Years of Consecutive Dividend Growth

Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Dividend History by Quarter for Abbott Laboratories (NYSE ABT)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/15/2017	quarterly	$0.27	2.05%	10/12/2017	10/13/2017	11/15/2017
6/9/2017	quarterly	$0.27	2.25%	7/12/2017	7/14/2017	8/15/2017
2/17/2017	quarterly	$0.27	2.36%	4/11/2017	4/14/2017	5/15/2017
12/9/2016	quarterly	$0.27	2.7%	1/11/2017	1/13/2017	2/15/2017
9/15/2016	quarterly	$0.26	2.48%	10/12/2016	10/14/2016	11/15/2016
6/10/2016	quarterly	$0.26	2.75%	7/13/2016	7/15/2016	8/15/2016
2/19/2016	quarterly	$0.26	2.66%	4/13/2016	4/15/2016	5/16/2016
12/11/2015	quarterly	$0.26	2.32%	1/13/2016	1/15/2016	2/16/2016
9/17/2015	quarterly	$0.24	2.22%	10/13/2015	10/15/2015	11/15/2015
6/12/2015	quarterly	$0.24	2%	7/13/2015	7/15/2015	8/15/2015
2/20/2015	quarterly	$0.24	2.03%	4/13/2015	4/15/2015	5/15/2015
12/12/2014	quarterly	$0.24	2.21%	1/13/2015	1/15/2015	2/13/2015
9/11/2014	quarterly	$0.22	2.07%	10/10/2014	10/15/2014	11/15/2014
6/13/2014	quarterly	$0.22	2.21%	7/11/2014	7/15/2014	8/15/2014
2/21/2014	quarterly	$0.22	2.26%	4/11/2014	4/15/2014	5/15/2014
10/16/2013	quarterly	$0.22	2.37%	1/13/2014	1/15/2014	2/15/2014
9/12/2013	quarterly	$0.14	1.61%	10/10/2013	10/15/2013	11/15/2013
6/14/2013	quarterly	$0.14	1.52%	7/11/2013	7/15/2013	8/15/2013
2/15/2013	quarterly	$0.14	1.61%	4/11/2013	4/15/2013	5/15/2013
12/14/2012	quarterly	$0.14	0.86%	1/11/2013	1/15/2013	2/15/2013

(Data available from 1/1/2013 forward)

Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)

Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 71.45%

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/26/2017	Daniel Gesua Sive Salvadori	Insider	Sell	62,460	$52.95	$3,307,257.00
9/22/2017	Jaime Contreras	Insider	Sell	52,700	$51.97	$2,738,819.00
8/16/2017	Stephen R Fussell	Insider	Sell	196,550	$49.50	$9,729,225.00
8/1/2017	Sharon J Bracken	Insider	Sell	2,000	$49.16	$98,320.00
7/27/2017	Brian J Blaser	Insider	Sell	15,000	$50.00	$750,000.00
7/25/2017	Hubert L Allen	Insider	Sell	4,600	$50.79	$233,634.00
6/15/2017	Jared Watkin	Insider	Sell	552	$47.97	$26,479.44
6/8/2017	Stephen R Fussell	Insider	Sell	196,550	$46.00	$9,041,300.00
4/27/2017	Roger Bird	Insider	Sell	5,600	$43.82	$245,392.00
4/26/2017	Joseph J Manning	Insider	Sell	4,200	$43.95	$184,590.00
3/1/2017	Michael J. Warmuth	Insider	Sell	3,851	$45.39	$174,796.89
2/23/2017	Robert E Funck	VP	Sell	25,500	$45.50	$1,160,250.00
2/22/2017	Roger Bird	Insider	Sell	13,222	$45.02	$595,254.44
2/21/2017	Deepak S Nath	Insider	Sell	319	$44.98	$14,348.62
1/31/2017	Heather L Mason	Insider	Sell	35,700	$40.77	$1,455,489.00
12/20/2016	Brian J Blaser	Insider	Buy	15,580	$38.45	$599,051.00
12/14/2016	Robert B Ford	Insider	Buy	12,775	$39.09	$499,374.75
11/10/2016	Miles D White	Chairman	Buy	121,456	$40.45	$4,912,895.20
11/1/2016	Sally E Blount	Director	Buy	5,100	$39.24	$200,124.00
9/26/2016	Daniel Gesua Sive Salvadori	SVP	Sell	815	$41.71	$33,993.65
7/28/2016	Stephen R Fussell	Insider	Sell	41,500	$45.00	$1,867,500.00
7/26/2016	Michael J Warmuth	Insider	Sell	26,800	$43.49	$1,165,532.00
7/25/2016	Miles D White	Chairman	Buy	242,547	$43.18	$10,473,179.46
7/25/2016	Robert E Funck	VP	Sell	26,800	$43.08	$1,154,544.00
6/28/2016	Hubert L Allen	EVP	Sell	3,400	$37.14	$126,276.00
6/15/2016	Jared Watkin	SVP	Sell	552	$37.63	$20,771.76
6/1/2016	Brian B Yoor	CFO	Sell	565	$39.49	$22,311.85
4/28/2016	Deepak S Nath	SVP	Sell	53	$41.31	$2,189.43
3/31/2016	Jaime Contreras	SVP	Sell	462	$41.78	$19,302.36
2/29/2016	Brian B Yoor	CFO	Sell	865	$39.12	$33,838.80
2/29/2016	Deepak S Nath	SVP	Sell	793	$39.27	$31,141.11
2/29/2016	Robert B Ford	EVP	Sell	1,706	$39.28	$67,011.68
2/29/2016	Robert E Funck	VP	Sell	1,333	$39.30	$52,386.90
2/22/2016	Jared Watkin	SVP	Sell	554	$39.09	$21,655.86
2/16/2016	Deepak S. Nath	SVP	Sell	171	$37.13	$6,349.23
12/16/2015	Miles D. White	CEO	Sell	438,000	$46.00	$20,148,000.00
8/18/2015	Stephen R. Fussell	EVP	Sell	13,096	$50.46	$660,824.16
4/27/2015	Heather L Mason	EVP	Sell	13,500	$47.45	$640,575.00
4/27/2015	Roger Bird	SVP	Sell	28,548	$47.57	$1,358,028.36
3/26/2015	J. Scott White	SVP	Sell	12,483	$46.68	$582,706.44
3/2/2015	Jaime Contreras	SVP	Sell	9,209	$47.34	$435,954.06
2/4/2015	John M Capek	EVP	Sell	34,292	$45.66	$1,565,772.72
11/25/2014	Jaime Contreras	SVP	Sell	51,600	$44.07	$2,274,012.00
10/29/2014	Miles D White	CEO	Sell	440,800	$42.52	$18,742,816.00
3/3/2014	John Landgraf	EVP	Sell	17,293	$39.38	$680,998.34
3/3/2014	Katherine Doyle	SVP	Sell	6,639	$39.01	$258,987.39
3/3/2014	Robert Funck	VP	Sell	1,413	$38.97	$55,064.61
2/18/2014	John Landgraf	EVP	Sell	1,583	$39.10	$61,895.30
1/29/2014	Michael Warmuth	EVP	Sell	11,430	$36.21	$413,880.30
12/6/2013	Jean-Yves Pavee	SVP	Sell	5,855	$37.46	$219,328.30
11/7/2013	Stephen Fussell	EVP	Sell	10,466	$37.59	$393,416.94
10/30/2013	Jaime Contreras	SVP	Sell	25,368	$36.85	$934,810.80
6/7/2013	Heather L Mason	SVP	Sell	12,000	$37.01	$444,120.00
2/1/2013	William A Osborn	Director	Buy	10,000	$33.86	$338,600.00

(Data available from 1/1/2013 forward)

Headline Trends for Abbott Laboratories (NYSE:ABT) Latest Headlines for Abbott Laboratories (NYSE:ABT)

Source:

Date	Headline
	Abbott Laboratories (ABT) Stock Rating Reaffirmed by Barclays PLC www.americanbankingnews.com - October 19 at 4:28 PM
	Abbott Labs (ABT) PT Raised to $65 at Jefferies - StreetInsider.com www.streetinsider.com - October 19 at 3:31 PM
	ABT earnings call for the period ending September 30, 2017 - Motley Fool www.fool.com - October 19 at 3:31 PM
	A Great Place to Do Great Things: Developing Game-Changing Technology at Abbott finance.yahoo.com - October 19 at 3:30 PM
	Abbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT) www.fool.com - October 19 at 2:43 PM
	Abbott Laboratories (ABT) Stock Rating Reaffirmed by Citigroup Inc. www.americanbankingnews.com - October 19 at 1:08 PM
	Abbott Laboratories (ABT) Rating Reiterated by BMO Capital Markets www.americanbankingnews.com - October 19 at 1:08 PM
	Abbott Laboratories (ABT) Price Target Raised to $6.00 at Morgan Stanley www.americanbankingnews.com - October 19 at 1:08 PM
	Abbott Laboratories' (ABT) Outperform Rating Reiterated at Cowen and Company www.americanbankingnews.com - October 19 at 11:44 AM
	Abbott Laboratories (ABT) PT Raised to $60.00 at Royal Bank Of Canada www.americanbankingnews.com - October 19 at 8:19 AM
	Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed - Nasdaq www.nasdaq.com - October 19 at 1:45 AM
	Abbott (ABT) Beats Earnings and Sales in Q3, Tweaks View - Nasdaq www.nasdaq.com - October 18 at 8:42 PM
	Abbott Labs (ABT) PT Raised to $63 at Stifel Following 3Q Release - StreetInsider.com www.streetinsider.com - October 18 at 8:42 PM
	Abbott Laboratories (ABT) call put ratio 2.86 calls to 1 put into Q3 - StreetInsider.com www.streetinsider.com - October 18 at 3:42 PM
	Abbott Laboratories' (ABT) CEO Miles White on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - October 18 at 3:42 PM
	Abbott (ABT) Beats Earnings and Sales in Q3, Tweaks View finance.yahoo.com - October 18 at 3:42 PM
	Abbott shares surge 1.6% after Q3 profit, revenue beats finance.yahoo.com - October 18 at 3:42 PM
	Abbott Delivers $100 Million Sales Beat On Pharma, Devices Strength finance.yahoo.com - October 18 at 3:42 PM
	Abbott's recent deals, medical device pipeline to fuel growth finance.yahoo.com - October 18 at 3:42 PM
	4 health stocks and a gamer in the Blitz finance.yahoo.com - October 18 at 3:42 PM
	Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed finance.yahoo.com - October 18 at 3:42 PM
	Abbott Laboratories (ABT) Issues Q4 Earnings Guidance www.americanbankingnews.com - October 18 at 9:10 AM
	Abbott Laboratories (ABT) Issues Earnings Results www.americanbankingnews.com - October 18 at 9:10 AM
	10 Stocks To Watch For October 18, 2017 feeds.benzinga.com - October 18 at 4:46 AM
	Emergent Biosolutions (EBS) & Abbott Laboratories (ABT) Head-To-Head Comparison www.americanbankingnews.com - October 18 at 12:14 AM
	Healthy Earnings Momentum Keeps Abbott Laboratories (ABT) a Buy - Investorplace.com (blog) investorplace.com - October 17 at 3:29 PM
	Henry Schein (HSIC) Inks Distribution Agreement with Terason finance.yahoo.com - October 17 at 3:29 PM
	Phibro Animal Banks on Diverse Portfolio, Competition Rife finance.yahoo.com - October 17 at 3:29 PM
	Healthy Earnings Momentum Keeps Abbott Laboratories (ABT) a Buy investorplace.com - October 17 at 10:02 AM
	Head-To-Head Review: Marinus Pharmaceuticals (MRNS) versus Abbott Laboratories (ABT) www.americanbankingnews.com - October 17 at 4:30 AM
	Patients Battling Complex Regional Pain Syndrome Find a Host of New Benefits in Abbott's Proclaim™ DRG System finance.yahoo.com - October 17 at 1:38 AM
	Zacks Investment Research Downgrades Abbott Laboratories (ABT) to Hold www.americanbankingnews.com - October 14 at 6:28 PM
	Assessing Abbott’s 3Q17 Expectations by Segment finance.yahoo.com - October 13 at 3:18 PM
	Abbott Banks on FDA Approvals and Buyouts, Competition Rife finance.yahoo.com - October 13 at 3:18 PM
	Abbott’s Analyst Recommendations ahead of Its 3Q17 Results finance.yahoo.com - October 12 at 8:37 PM
	Inside Abbott’s 3Q17 Revenue Expectations: Hit or Miss? finance.yahoo.com - October 12 at 3:32 PM
	What to Expect from Abbott Laboratories’ 3Q17 Earnings finance.yahoo.com - October 12 at 3:32 PM
	Abbott Laboratories (ABT) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - October 12 at 8:08 AM
	Comparing Abbott Laboratories (ABT) & XenoPort (XNPT) www.americanbankingnews.com - October 12 at 4:32 AM
	Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 12, 2017 - Nasdaq www.nasdaq.com - October 11 at 3:35 PM
	Dividend Coverage: This Healthcare Company has Paid Consecutive Quarterly Divided Since 1924; Will Trade Ex-Dividend on October 12, 2017 finance.yahoo.com - October 11 at 3:35 PM
	Is a Beat in Store for Abbott (ABT) This Earnings Season? finance.yahoo.com - October 11 at 3:35 PM
	Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business finance.yahoo.com - October 11 at 3:35 PM
	QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife finance.yahoo.com - October 11 at 3:35 PM
	Abbott Laboratories (ABT) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - October 11 at 1:38 AM
	Abbott Laboratories (ABT) Raised to Buy at Zacks Investment Research www.americanbankingnews.com - October 10 at 11:26 PM
	Ex-Dividend Reminder: Abbott Laboratories, Becton, Dickinson and Pennymac Mortgage Investment Trust - Nasdaq www.nasdaq.com - October 10 at 3:30 PM
	Abbott Laboratories (ABT) Raised to Buy from a Hold \| InvestorPlace - Investorplace.com www.investorplace.com - October 10 at 3:30 PM
	Illumina (ILMN) Strong on Product Launches, Competition Rife finance.yahoo.com - October 10 at 3:30 PM
	QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite finance.yahoo.com - October 10 at 3:30 PM